Stroke prevention in atrial fibrillation

Cardiovascular Drugs and Therapy

Volumn 25, Issue 6, 2011, Pages 561-570

  Piccini, Jonathan P ^a   Wallace, Thomas W ^b   Patel, Manesh R ^a   Becker, Richard C ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Heart Clinic Arkansas   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Bleeding; Direct thrombin inhibitors; Factor Xa inhibitors; Risk stratification; Stroke; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; ARISTOTLE; CLOPIDOGREL; DABIGATRAN; EDOXABAN; ENOXAPARIN; HEPARIN; RIVAROXABAN; TECARFARIN; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; BLEEDING; DRUG BIOAVAILABILITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY CLEARANCE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; STROKE; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK; STROKE;

EID: 83055172784     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6334-4     Document Type: Article

References (57)

1. AS Go EM Hylek KA Phillips, et al. 2001 Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study JAMA 285 2370 2375 11343485 1:STN:280:DC%2BD3M3ntleitQ%3D%3D (Pubitemid 32424106)
2. Y Miyasaka ME Barnes BJ Gersh, et al. 2006 Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 119 125 16818816 (Pubitemid 44420743)
3. PA Wolf RD Abbott WB Kannel 1991 Atrial fibrillation as an independent risk factor for stroke: the Framingham study Stroke 22 983 988 1866765 1:STN:280:DyaK3Mzislektg%3D%3D
4. EJ Benjamin D Levy SM Vaziri RB D'Agostino AJ Belanger PA Wolf 1994 Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study JAMA 271 840 844 8114238 1:STN:280: DyaK2c7lvVSksg%3D%3D
5. DM Lloyd-Jones TJ Wang EP Leip, et al. 2004 Lifetime risk for development of atrial fibrillation: the Framingham heart study Circulation 110 1042 1046 15313941 (Pubitemid 39319000)
6. V Fuster LE Ryden DS Cannom, et al. 2006 ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 e257 e354 16908781 (Pubitemid 44252297)
7. TJ Wang MG Larson D Levy, et al. 2003 Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart study Circulation 107 2920 2925 12771006 (Pubitemid 36736633)
8. AD Krahn J Manfreda RB Tate FA Mathewson TE Cuddy 1995 The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study Am J Med 98 476 484 7733127 1:STN:280: DyaK2M3ltVyjsw%3D%3D
9. MC Fang AS Go Y Chang, et al. 2007 Death and disability from warfarin-associated intracranial and extracranial hemorrhages Am J Med 120 700 705 17679129 (Pubitemid 47176507)
10. SN Singh XC Tang BN Singh, et al. 2006 Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a veterans affairs cooperative studies program substudy J Am Coll Cardiol 48 721 730 16904540 (Pubitemid 44175705)
11. P Dorian M Paquette D Newman, et al. 2002 Quality of life improves with treatment in the Canadian trial of atrial fibrillation Am Heart J 143 984 990 12075253 (Pubitemid 34666888)
12. ME Hamer JA Blumenthal EA McCarthy BG Phillips EL Pritchett 1994 Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia Am J Cardiol 74 826 829 7942563 1:STN:280:DyaK2M%2FivFSmuw%3D%3D (Pubitemid 24312984)
13. MR Reynolds V Essebag P Zimetbaum DJ Cohen 2007 Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry J Cardiovasc Electrophysiol 18 628 633 17451468 (Pubitemid 46800517)
14. JJ Caro 2004 An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation Am J Manag Care 10 S451 S458 15696909 discussion S8-61
15. RG Hart LA Pearce 2009 Current status of stroke risk stratification in patients with atrial fibrillation Stroke 40 2607 2610 19461020
16. S Seshadri A Beiser M Kelly-Hayes, et al. 2006 The lifetime risk of stroke: estimates from the Framingham study Stroke 37 345 350 16397184 (Pubitemid 43731985)
17. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57.
18. BF Gage AD Waterman W Shannon M Boechler MW Rich MJ Radford 2001 Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2864 2870 11401607 1:STN:280:DC%2BD3MzntFKgsQ%3D%3D (Pubitemid 32537350)
19. Meschia JF, Merrill P, Soliman EZ, et al. Racial disparities in awareness and treatment of atrial fibrillation: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Stroke.;41:581-7.
20. K Lakshminarayan CA Solid AJ Collins DC Anderson CA Herzog 2006 Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002) Stroke 37 1969 1974 16809573 (Pubitemid 44309888)
21. The atrial fibrillation follow-up investigation of rhythm management I. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33.
22. SJ Connolly A Laupacis M Gent RS Roberts JA Cairns C Joyner 1991 Canadian Atrial Fibrillation Anticoagulation (CAFA) study J Am Coll Cardiol 18 349 355 1856403 1:STN:280:DyaK3MzhtV2nuw%3D%3D
23. SJ Connolly MD Ezekowitz S Yusuf, et al. 2009 Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139 1151 19717844 1:CAS:528:DC%2BD1MXhtFOjsLnN
24. MC Fang AS Go Y Chang L Borowsky NK Pomernacki DE Singer 2008 Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation J Am Coll Cardiol 51 810 815 18294564 (Pubitemid 351253746)
25. GY Lip 2008 Risk factors and stroke risk stratification for atrial fibrillation: limitations and new possibilities Am Heart J 156 1 3 18585489
26. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-72.
27. PM Ridker E Danielson FAH Fonseca, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195 2207 18997196 1:CAS:528:DC%2BD1cXhtl2gurnL
28. JP DiMarco G Flaker AL Waldo, et al. 2005 Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study Am Heart J 149 650 656 15990748
29. R Pisters DA Lane R Nieuwlaat CB de Vos HJ Crijns GY Lip 2010 A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey Chest 138 1093 1100 20299623
30. DE Singer Y Chang MC Fang, et al. 2009 The net clinical benefit of warfarin anticoagulation in atrial fibrillation Ann Intern Med 151 297 305 19721017
31. PJ Devereaux DR Anderson MJ Gardner, et al. 2001 Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study BMJ 323 1218 1222 11719412 1:STN:280:DC%2BD3MnntlSitA%3D%3D
32. SA Hunt WT Abraham MH Chin, et al. 2009 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 e391 e479 19324966
33. JP Piccini AF Hernandez X Zhao, et al. 2009 Quality of care for atrial fibrillation among patients hospitalized for heart failure J Am Coll Cardiol 54 1280 1289 19778670 1:CAS:528:DC%2BD1MXhtlCgs7zJ
34. DE Singer GW Albers JE Dalen, et al. 2008 Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 546S 592S 18574273 1:CAS:528:DC%2BD1cXptVKhs74%3D (Pubitemid 351892972)
35. RG Hart LA Pearce MI Aguilar 2007 Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 857 867 17577005 (Pubitemid 351650486)
36. SB Jeffrey LB David CB Richard 2008 Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis Am J Med 121 43 49
37. DA Garcia S Regan LE Henault, et al. 2008 Risk of thromboembolism with short-term interruption of warfarin therapy Arch Intern Med 168 63 69 18195197 1:CAS:528:DC%2BD1cXhslSntbo%3D
38. GC Flaker M Gruber SJ Connolly, et al. 2006 Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials Am Heart J 152 967 973 17070169 1:CAS:528:DC%2BD28XhtFertb3I (Pubitemid 44637136)
39. F Dentali JD Douketis W Lim M Crowther 2007 Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials Arch Intern Med 167 117 124 17242311 1:CAS:528:DC%2BD2sXhvFKms7w%3D (Pubitemid 46148058)
40. PP Karjalainen P Porela A Ylitalo, et al. 2007 Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting Eur Heart J 28 726 732 17267456 1:CAS:528:DC%2BD2sXlt1Ojt70%3D (Pubitemid 46439228)
41. Lopes RD, Starr A, Pieper CF, et al. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med.;123:134-40.
42. H Calkins J Brugada DL Packer, et al. 2007 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) task force on catheter and surgical ablation of atrial fibrillation Hear Rhythm 4 816 861 (Pubitemid 46850611)
43. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol.;55:735-43.
44. JL Anderson BD Horne SM Stevens, et al. 2007 Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 2563 2570 17989110 1:CAS:528:DC%2BD2sXhtlagsb3F (Pubitemid 350179221)
45. SJ Connolly J Pogue RG Hart, et al. 2009 Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2066 2078 19336502
46. GW Albers HC Diener L Frison, et al. 2005 Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 690 698 15701910
47. CJ Boos GYH Lip 2006 Ximelagatran: an eulogy Thromb Res 118 301 304 16626788 1:CAS:528:DC%2BD28Xntlyqt7o%3D (Pubitemid 44067201)
48. MG Bousser J Bouthier HR Buller, et al. 2008 Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial Lancet 371 315 321 18294998 1:STN:280:DC%2BD1c7js1Gmsg%3D%3D
49. BF Gage 2009 Can we rely on RE-LY? N Engl J Med 361 1200 1202 19717843 1:CAS:528:DC%2BD1MXhtFOjsLnE
50. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17.
51. Mahaffey KW. Rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). In: American Heart Association Scientific Sessions; 2010 November 15, 2010; Chicago; 2010.
52. DJ Ellis MH Usman PG Milner DM Canafax MD Ezekowitz 2009 The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation Circulation 120 1029 1035 19738136 1:CAS:528: DC%2BD1MXhtFamsLrF 2 p following 35
53. TJ Wang JM Massaro D Levy, et al. 2003 A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham heart study JAMA 290 1049 1056 12941677 (Pubitemid 37430445)
54. DE Singer GW Albers JE Dalen AS Go JL Halperin WJ Manning 2004 Antithrombotic therapy in atrial fibrillation: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 429S 456S 15383480 1:CAS:528:DC%2BD2cXptV2msbg%3D (Pubitemid 39302603)
55. RG Hart LA Pearce R McBride RM Rothbart RW Asinger 1999 Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) investigators Stroke 30 1223 1229 10356104 1:STN:280:DyaK1M3osVOguw%3D%3D (Pubitemid 29259178)
56. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011. Epub ahead of print.
57. Granger CB, Alexander JH, McMurrary JJ, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011. Epub ahead of print.